Full Breakdown
Settlement Reached in Henrietta Lacks Case Against Novartis
2/27/2026, 8:47:59 AM
Overview of the Settlement
The estate of Henrietta Lacks has reached a confidential settlement with Novartis, concluding a lawsuit that alleged the pharmaceutical company profited from the unauthorized use of Lacks' cells, known as HeLa cells, which were taken without her consent in 1951. The agreement, finalized in federal court in Maryland, resolves litigation that began in August 2024, where the estate sought the full amount of profits derived from the commercialization of these cells.
Background on Henrietta Lacks and HeLa Cells
Henrietta Lacks, a poor tobacco farmer from Virginia, had her cervical cancer cells extracted during treatment at Johns Hopkins Hospital in Baltimore. These cells became the first immortalized human cell line, allowing for continuous growth in laboratories. HeLa cells have played a crucial role in numerous medical advancements, including the development of the polio vaccine and COVID-19 research. Despite their significant contributions to science, Lacks' family did not receive compensation until recent legal actions were taken.
Key Legal Actions and Ongoing Litigation
The settlement with Novartis marks the second resolution for the Lacks estate, following a similar agreement with Thermo Fisher Scientific in 2023. The estate continues to pursue claims against Viatris and Ultragenyx Pharmaceutical, alleging that these companies also profited from the use of Lacks' cells. The ongoing litigation raises questions about ethical practices in medical research, particularly regarding consent and the exploitation of marginalized individuals.
Official Statements
In a joint statement, representatives from both the Lacks estate and Novartis expressed satisfaction with the resolution, stating they were "pleased they were able to find a way to resolve this matter filed by Henrietta Lacks' Estate outside of court." They declined to provide further details about the settlement.
Criticism and Opposition
Critics of the biomedical industry highlight the systemic issues surrounding the extraction and commercialization of human tissues without consent, particularly in the context of racial disparities in healthcare. The lawsuits filed by the Lacks estate underscore the historical injustices faced by Black patients in medical research, prompting calls for more stringent regulations and ethical standards.
Products Developed Using HeLa Cells
The lawsuit against Novartis specifically cited the company's use of HeLa cells in developing various medical products, including the herpes treatment Famvir, CAR-T therapy Kymriah, and gene therapy Zolgensma. Viatris was also implicated for its use of Lacks' cells in treatments like the antidepressant mirtazapine and the herpes medication Denavir.
Verbatim Quotes
- “Members of the family of Henrietta Lacks and Novartis are pleased they were able to find a way to resolve this matter filed by Henrietta Lacks’ Estate outside of court,” — Joint Statement from Novartis and the Lacks Estate
- “The lawsuits hearken back to an era when racism was rampant in the healthcare system.” — Legal Commentary on the Lacks Estate Lawsuits
The settlement with Novartis represents a significant step in addressing the legacy of Henrietta Lacks and the ethical implications of medical research practices. As the estate continues its pursuit of justice against other companies, the case remains a pivotal example of the intersection between race, ethics, and medical innovation.
